Mind Medicine SEC Filings

Dan Karlin, Chief Medical Officer of Mind Medicine (MNMD), reported a transaction dated 09/25/2025 in which 7,704 common shares were disposed of at $9.77 per share. The filing states these shares were sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units under a Rule 10b5-1 plan adopted on June 14, 2022. After the reported disposition, the reporting person beneficially owns 430,625 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Karlin on 09/26/2025.

Mind Medicine (MNMD) Form 144 notice discloses a proposed sale of 11,278 common shares by an insider through Morgan Stanley Smith Barney, with an aggregate market value of $110,216.51. The filer indicates the shares were acquired on 09/25/2025 as restricted stock vesting under a registered plan and the intended method of payment is compensation. The sale is listed with an approximate sale date of 09/25/2025 on NASDAQ. The filing also reports a prior sale by Mark Sullivan of 11,491 shares on 06/25/2025 for $78,169.83. The notice includes the standard insider representation about lack of undisclosed material information.

Mind Medicine (MNMD) Form 144 shows an intended sale of 7,704 common shares by a person for whose account the securities were issued, through Morgan Stanley Smith Barney LLC on 09/25/2025 on NASDAQ. The filing reports an aggregate market value of $75,288.88 for the shares and lists 76,087,943 shares outstanding for the issuer. The shares to be sold were acquired the same day, 09/25/2025, as restricted stock vesting under a registered plan and payment is recorded as Not Applicable. The filing also discloses a prior sale by DANIEL ROLLINGS KARLIN of 7,848 shares on 06/25/2025 for gross proceeds of $53,387.59. The notice includes the required signature representation regarding absence of undisclosed material adverse information.

Form 144 notice for Mind Medicine (MNMD): The filing records a proposed sale of 25,797 common shares with an aggregate market value of $252,106.34 through Morgan Stanley Smith Barney LLC on 09/25/2025 on Nasdaq. The shares were acquired the same day as restricted stock vesting under a registered plan and payment is listed as Not Applicable. The form also discloses a prior sale by Robert B Barrow of 26,491 shares on 06/25/2025 for gross proceeds of $180,210.33. The filer attests there is no undisclosed material adverse information and the standard signature and legal warning language appear.

Mind Medicine (MindMed) Inc. (MNMD) – Form 4 insider transaction:

Chief Legal Officer Mark Sullivan reported the sale of 11,491 common shares on 25-Jun-2025. The shares were automatically sold (transaction code “S”) to cover withholding-tax liabilities triggered by the settlement of vested RSUs. The disposition was executed under a Rule 10b5-1 plan adopted 14-Mar-2024, indicating the trade was pre-scheduled and not discretionary.

The weighted-average sales price was $6.80, with individual trades carried out between $6.67 and $7.03. After the sale, Sullivan directly owns 305,130 shares, meaning the transaction reduced his position by roughly 3.6 %. No derivative securities were involved, and the filing was signed on 26-Jun-2025.

• The activity appears routine, tax-driven and represents a small fraction of the executive’s holdings.
• Provides investors with an indicative trading range for MNMD at the end of June 2025.

Given the limited size and tax-related nature, the sale is unlikely to carry significant fundamental implications, though it is the first insider disposition tied to this RSU vesting cycle.